Why the Nootropics Industry Has a Trust Problem — And How Data Fixes It

The nootropics market is projected to hit $30B by 2028. It's also one of the least trusted segments in consumer health. And honestly? That's earned. The industry has spent two decades making claims it can't back up with data, relying on cherry-picked studies and influencer marketing instead of actual outcome measurement.

Here's what most nootropic companies don't want you to think about: if their product genuinely worked as advertised, they'd be falling over themselves to publish user outcome data. The fact that almost none of them do tells you everything. It's easier to sell a narrative than to prove a result.

NooStack exists because I got tired of the guessing game. I was personally spending $200/month on cognitive supplements with zero way to measure whether they were doing anything beyond placebo. The Cognitive Performance Index we're building isn't just a product feature — it's a forcing function for honesty in the entire space.

When you give users standardized tools to measure their own cognitive performance — reaction time, working memory span, sustained attention — and let them correlate those metrics with their supplement routines, two things happen. First, the products that work get validated with real data. Second, the products that don't work get exposed. That's not a bug. That's the entire point.

The companies that survive the next wave of the nootropics market will be the ones that welcome measurement. The rest will get filtered out by an increasingly data-literate consumer base.